Project Orbis Nears 30 Approvals In Oncology; Could China Be Added?

A review of drugs and supplemental uses since the project’s inception shows roughly one-third of the products reviewed have been NMEs.

Confidentiality issues could be slowing US/China regulatory collaborations. • Source: Nielsen Hobbs

More from Review Pathways

More from Pathways & Standards